# Epithelial extracellular vesicles induce inflammation and neutrophil activation in the Pseudomonas aeruginosa infected cystic fibrosis bronchial epithelium

**Authors:** Meghan June Hirsch, Kuen-You Tsai, Luke I. Jones, Angela N. Morales, Hannah J. McIntire-Ray, Patrick H. Howze IV, Jarrod W. Barnes, Camilla Margaroli, Kristopher Genschmer, Stefanie Krick

PMC · DOI: 10.3389/fimmu.2025.1659951 · Frontiers in Immunology · 2026-01-14

## TL;DR

This study shows that extracellular vesicles from infected CF lung cells increase inflammation and neutrophil activity, which may contribute to chronic lung disease in cystic fibrosis.

## Contribution

The study reveals a novel role of epithelial extracellular vesicles in promoting inflammation in Pseudomonas-infected cystic fibrosis lungs.

## Key findings

- EVs from PA-infected CF cells increased IL-6, IL-8, and TNFα expression in CF cells.
- EVs activated neutrophils but had no effect on control cells.
- ETI treatment did not reduce the pro-inflammatory effects of EVs.

## Abstract

Cystic fibrosis (CF) is an autosomal recessive disorder, which manifests in many organ systems including the lungs. Chronic inflammation is a hallmark of CF lung disease leading to bronchiectasis and lung function decline. This is worsened by airway colonization and recurrent infections due to opportunistic pathogens such as Pseudomonas aeruginosa [PA], but the crosstalk between host-bronchial epithelium and immune system has been under characterized. Extracellular vesicles have been found to mediate intercellular crosstalk in different lung diseases and EVs have been shown to be increased in the bronchoalveolar fluid of CF patients. We hypothesize that EVs from PA-infected CF bronchial epithelial cells can modulate pro-inflammatory cytokines and neutrophil migration and activation in an autocrine and paracrine manner.

CF bronchial epithelial cells (CFBEs) and control bronchial epithelial cells (16HBEs) were infected with PA for 24 hours followed by EV isolation, which were used to treat uninfected CFBE and 16HBEs to assess expression and secretion of pro-inflammatory markers. In addition, the effects of EVs on neutrophil migration and activation were determined as well as the role of CFTR deficiency by using CFTR modulator therapy (Elexacaftor/Tezacaftor/Ivacaftor).

EVs derived from PA infected CFBEs (EVpPAs) increased IL-6, IL-8, and TNFα expression and neutrophil activation in CFBEs but not in 16HBEs. Interestingly, the effect of EVpPAs on inflammation was not attenuated by pre-treatment with ETI.

EVs from the PA-infected CF bronchial epithelium seem to facilitate an autocrine and paracrine pro-inflammatory response that is not attenuated by ETI treatment, suggesting a novel contribution of EVs to the chronic inflammatory phenotype observed in the PA-infected CF lung.

## Linked entities

- **Proteins:** CFTR (CF transmembrane conductance regulator)
- **Chemicals:** Elexacaftor (PubChem CID 134587348), Tezacaftor (PubChem CID 46199646), Ivacaftor (PubChem CID 16220172)
- **Diseases:** Cystic fibrosis (MONDO:0009061), bronchiectasis (MONDO:0004822)

## Full-text entities

- **Diseases:** autosomal recessive disorder (MESH:D030342), CF lung disease (MESH:C563237), lung function decline (MESH:D055370), infected (MESH:D007239), lung diseases (MESH:D008171), CFTR deficiency (MESH:D007153), PA (MESH:D011552), Chronic inflammation (MESH:D007249), bronchiectasis (MESH:D001987), CF (MESH:D003550)
- **Chemicals:** ETI (-), Ivacaftor (MESH:C545203), Tezacaftor (MESH:C000625213), Elexacaftor (MESH:C000629074)
- **Species:** Pseudomonas aeruginosa (species) [taxon 287], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12846939/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12846939/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12846939/full.md

---
Source: https://tomesphere.com/paper/PMC12846939